Selective Androgen Receptor Modulator, YK11, Regulates Myogenic Differentiation of C2C12 Myoblasts by Follistatin Expression

Overview of attention for article published in Biological and Pharmaceutical Bulletin, January 2013

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (85th percentile)
High Attention Score compared to outputs of the same age and source (92nd percentile)

So far, Altmetric has seen 10 X posts from 6 X users, with an upper bound of 9,902 followers.

@RockstrohAndrew @leahcasciano @jmashh_ SARMs were developed by Big Pharma. So they had to be tested in approved lab settings. These are just a few studies. I’ve extensively looked into the research for the last 4 yrs https://t.co/2n9kGlhRh9 https://t.co

YK11, Is it a SARM or a Myostatin Inhibitor? How about BOTH! https://t.co/PDomsUI91W

YK11; The Dual Pathway Anabolic Sarm: https://t.co/gCuflLJovY We carry it for your research purposes!

YK11; The Dual PAthway Anabolic Sarm: https://t.co/gCuflLJovY

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 6 additional X posts.